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Abstract
Background: An aging population, with its associated rise in cancer incidence and strain on the oncology workforce, will
continue to motivate patients, healthcare providers and policy makers to better understand the existing and growing
challenges of access to chemotherapy. Administrative data, and SEER-Medicare data in particular, have been used to
assess patterns of healthcare utilization because of its rich information regarding patients, their treatments, and their
providers. To create measures of geographic access to chemotherapy, patients and oncologists must first be identified.
Others have noted that identifying chemotherapy providers from Medicare claims is not always straightforward, as
providers may report multiple or incorrect specialties and/or practice in multiple locations. Although previous studies
have found that specialty codes alone fail to identify all oncologists, none have assessed whether various methods of
identifying chemotherapy providers and their locations affect estimates of geographic access to care.
Methods: SEER-Medicare data was used to identify patients, physicians, and chemotherapy use in this population-based
observational study. We compared two measures of geographic access to chemotherapy, local area density and distance
to nearest provider, across two definitions of chemotherapy provider (identified by specialty codes or billing codes) and
two definitions of chemotherapy service location (where chemotherapy services were proven to be or possibly available)
using descriptive statistics. Access measures were mapped for three representative registries.
Results: In our sample, 57.2 % of physicians who submitted chemotherapy claims reported a specialty of hematology/
oncology or medical oncology. These physicians were associated with 91.0 % of the chemotherapy claims. When
providers were identified through billing codes instead of specialty codes, an additional 50.0 % of beneficiaries
(from 23.8 % to 35.7 %) resided in the same ZIP code as a chemotherapy provider. Beneficiaries were also 1.3
times closer to a provider, in terms of driving time. Our access measures did not differ significantly across
definitions of service location.
Conclusions: Measures of geographic access to care were sensitive to definitions of chemotherapy providers; far
more providers were identified through billing codes than specialty codes. They were not sensitive to definitions
of service locations, as providers, regardless of how they are identified, generally provided chemotherapy at each
of their practice locations.
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Background
Patients who live in areas where chemotherapy providers
are scarce must travel extended distances to receive
treatment [1–3]. Research suggests that some patients
who may benefit from chemotherapy remain untreated
because of where they live [1, 2, 4–6]. Thus measures of
geographic access to chemotherapy have been constructed
to better understand these potential barriers to treatment.
The two most common geographic access to care mea-
sures include local area density and distance to the nearest
chemotherapy provider [1, 7–9]. To construct these mea-
sures, researchers must accurately identify chemotherapy
providers and their service locations. Failure to account
for all types of service locations can bias estimates of geo-
graphic access to chemotherapy. For example, in a recent
study, the median driving time to the nearest chemother-
apy provider decreased from 51.6 to 19.2 min when visit-
ing consulting clinics were included [10].
Measures of geographic access to chemotherapy are
often created using Medicare claims because they offer
detailed information regarding treatments, providers and
patients [11]. Unfortunately, even with this information,
creating measures of geographic access to chemotherapy
is not completely straightforward, as noted in the litera-
ture [12, 13]. Baldwin et al. state that researchers may
need to distinguish between those who claim to be on-
cologists (through specialty codes) and those who do the
work of an oncologist (through billing codes) when iden-
tifying chemotherapy providers [12]. They also acknow-
ledge that identifying service locations is not trivial, as
providers can and do practice at more than one location
[12]. Should researchers assume that chemotherapy can
only be provided at locations where it has been in the
past, i.e. “proven” service locations? Or is reasonable to
assume that chemotherapy may be available at each
practice location, i.e. “possible” service locations?
Although the challenges of identifying providers and
service locations have been previously noted, no research
has quantified the effect of these various definitions on
measures of geographic access to care. As there exists no
standard protocol in how to define providers and locations,
the definitions vary across studies. Some have used specialty
codes to identify providers [14–16]. One paper used billing
codes [17] and another used both billing and specialty
codes [5]. Another strategy has been to supplement Medi-
care data with outside sources, such as the American
Medical Association (AMA) physician masterfile or the
Area Health Resource Files [1, 2, 4, 18–20]. Although doing
so has been shown to capture more oncologists [12, 13],
our objective was slightly different. We were interested in
how various methods of identifying chemotherapy pro-
viders and locations impacted the two most commonly
used measures of geographic access to chemotherapy: local
area density and distance to nearest provider.
Methods
Data
We used retrospective data from the 2006 Surveillance,
Epidemiology and End Results (SEER)-Medicare data-
base. As a network of population-based cancer registries,
SEER currently covers approximately 28 % of the U.S.
population [21]. SEER-Medicare data is often used to study
geographic access to chemotherapy for cancer patients be-
cause it offers detailed patient and provider information
[11, 22].
Beneficiary ZIP code was abstracted from the SEER Pa-
tient Entitlement and Diagnosis Summary File (PEDSF)
file. Medicare claims were used to identify chemotherapy
use, provider specialty, and service location. We limited
our analysis to the Carrier claims because only these re-
port both provider specialty and location information.
Driving times were calculated by Microsoft MapPoint. We
chose driving-time distance instead of a straight Euclidian
distance, i.e. “as the crow flies,” to account for topology
(e.g. mountains, lakes, etc.) and their associated road
structures, along with variations in travel time due to
speed limits.
To create our study cohort, we excluded unmatched
ZIP codes. In 2006 35,206 Medicare beneficiaries across
the 18 SEER registries were diagnosed with lung cancer.
After excluding the beneficiaries for whom distances
could not be calculated (N = 46) and whose residence
ZIP code did not map onto a SEER registry according to
MapPoint (N = 764), our final sample included 34,396
beneficiaries and their claims. Our methodology, which
consisted of 2x2 possible ways of identifying providers
and locations, is visually depicted (Fig. 1).
Identifying chemotherapy providers
When we identified chemotherapy providers by specialty
codes, individuals reporting a Hematology/Oncology (83)
or Medical Oncology (90) specialty code on any claim
were included. This would also apply to providers who
reported multiple specialties among their claims. With
this methodology, it is possible for an individual to not be
labeled a chemotherapy provider even if they repeatedly
billed for chemotherapy because an oncology specialty
code was never reported. Chemotherapy providers were
also identified through chemotherapy-related billing
codes, Healthcare Common Procedure Coding System
(HCPCS) codes and International Classification of Diseases,
Clinical Modification diagnosis codes (ICD9-CM DX), pro-
vided by the SEER-Medicare program [23] and reported in
Table 1. Hence an individual was considered a chemother-
apy provider if they billed for chemotherapy-related ser-
vices. With this method, it was possible for individuals who
reported an oncology specialty code on claims to not be
labeled an oncologist because none of their claims were
chemotherapy related.
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Identifying chemotherapy service locations
Chemotherapy service locations were defined as either
“possible” or “proven.” Proven service locations included
only the practice locations from which providers billed
Medicare for chemotherapy-related services. Possible
service locations included all of a provider’s practice lo-
cations, regardless of whether a particular location ever
filed a chemotherapy-related claim, under the assump-
tion that each location could provide chemotherapy. The
first method provides then a lower-bound estimate of
service locations and the second an upper bound.
Geographic access to chemotherapy measures
For a total of four possible specifications (specialty codes
to identify provider and their proven service locations;
specialty codes to identify provider and their possible
service locations; billing codes to identify providers and
their proven service locations; and billing codes to identify
providers and their possible service locations), we esti-
mated the two most commonly used measures of geo-
graphic access to chemotherapy: local area density and
distance to nearest chemotherapy provider [24–26]. Mea-
sures of local area density form the basis for the increas-
ingly popular floating catchment area methods and kernel
density estimation methods [26]. In this paper, local area
density was calculated by summing the number of unique
chemotherapy providers within a 20-min driving-time
radius from each beneficiary’s ZIP code centroid. Distance
to nearest oncologist was calculated by the driving-time
distance, in minutes, between centroids. If the beneficiary
resided in the same ZIP code as the nearest chemotherapy
service location, the distance between the two was set to
zero. It is important to note that these measure potential
access to chemotherapy and not actual utilization.
We calculated descriptive statistics and assessed differ-
ences between the estimates with Student’s t-tests. All
analyses were conducted using SAS Software, version 9.3.
Maps were created using Microsoft MapPoint 2013 for
three representative SEER registries (Iowa, Connecticut
and New Jersey) which vary in their degree of rurality.
Results
Among the 216,438 unique providers with usable ZIP
code information who cared for our study population in
any capacity, 4,424 reported an oncology specialty code
and 6,253 billed Medicare for a chemotherapy-related
service. These 4,424 providers, as defined by specialty
codes, provided chemotherapy in 5,076 locations (proven
service locations) and practiced in a total of 5,157 locations
Fig. 1 Algorithm for estimating measures of geographic access to chemotherapy. Two definitions of chemotherapy provider and two definitions
of service locations are considered
Table 1 Codes used to identify chemotherapy-related services
in Medicare Carrier claims
Type of Code Codes
HCPCS 96400-96549, J9000-J9999, Q0083-Q0085
ICD9-CM DX V581, V662, V672
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(possible service locations). The 6,253 providers, as defined
by chemotherapy billing codes, provided chemotherapy in
6,722 locations and practiced in 8,101 locations. Thus, on
average, providers administered chemotherapy in 1.08-1.30
locations, depending on how provider and service locations
were defined.
Specialty codes and chemotherapy-related claims
Of the 6,253 unique providers who billed for chemotherapy-
related services, 541 (8.7 %) reported more than one
specialty and none were missing. The top four specialties
reported by unique physicians included hematology/oncol-
ogy (42.1 %), medical oncology (15.1 %), urology (9.8 %),
and internal medicine (6.0 %). The two specialties of
hematology/oncology and medical oncology comprised
57.2 % of the physicians.
However when we categorized the chemotherapy-
related claims by specialty, we found that 91.0 % of the
claims reported either a specialty of hematology/oncol-
ogy (65.7 %) or medical oncology (25.3 %). The two next
most commonly reported specialty on the claims were
hematology (3.1 %) and internal medicine (2.9 %). This
would indicate that, although self-reported oncologists
are not the only ones administering chemotherapy, they are
the ones who provide most of the observed chemotherapy-
related services. We conducted an ad hoc analysis to
confirm. Of physicians who reported only one specialty
(N = 5,712), each hematologist/oncologist (medical on-
cologist) submitted on average 380.1 (388.8) chemo-
therapy claims during the study period. In contrast,
each internist and urologist submitted on average 54.2,
10.0 claims, respectively.
Geographic measures of access to chemotherapy
After characterizing the specialties associated with the
claims, we estimated the two geographic access to care
measures using the various provider and location defini-
tions. We discuss results only for the proven locations,
as access measures did not differ statistically across
service location definitions.
Specialty codes to identify chemotherapy provider
Identifying chemotherapy providers by specialty codes,
we found on average 21.1 (SD = 29.8) providers within
20 min of a beneficiary, with a median value of 8
(Table 2). Almost 75 % of beneficiaries had access to at
least one chemotherapy provider within 20 min. The
driving-time distance to the nearest chemotherapy pro-
vider was on average 16.1 min (SD = 20.3). Half of the
sample was within 10.7 min of a provider and patients
in the 95th percentile would need to drive 51.9 min to
get to the nearest provider. These driving-time estimates
are skewed towards zero because we are unable to assess
distances within the same ZIP code. Thus, we also report
the percent of patients that resided in the same ZIP code
as a chemotherapy provider (Table 3). Overall, 23.8 % of
beneficiaries resided in the same ZIP code as a chemo-
therapy provider, when defined by specialty code.
Billing codes to identify chemotherapy provider
We identified a substantially larger number of chemo-
therapy providers through chemotherapy billing codes.
With this definition, beneficiaries had on average 41.9
(SD = 52.3) providers within 20 min, 2.0 times more than
when identified by specialty codes (p-value < 0.0001). Driv-
ing time also decreased when identifying chemotherapy
provider through billing codes. With this definition, benefi-
ciaries were on average 12.2 (SD = 16.6) minutes away from
a chemotherapy provider, 1.3 times closer than when iden-
tified by specialty codes (p-value < 0.0001). Over three
quarters (79.4 %) had access to at least one chemotherapy
provider within 20 min and over a third (35.7 %) resided in
the same ZIP code as a chemotherapy provider, a 50.0 %
increase compared to identifying providers through spe-
cialty code (p < 0.0001).
Geographic variation in access to chemotherapy
Geographic access to chemotherapy (defined here as any
provider practicing in their proven locations within 20 min
of a beneficiary) was mapped for three representative SEER
registries in Fig. 2. Panel A identified chemotherapy
providers through specialty codes and panel B through
chemotherapy billing codes. Brownish-grey areas signify
that no beneficiary was diagnosed with lung-cancer in that
ZIP code during the study period. Regardless of which
method was used to identify providers, fewer Iowa benefi-
ciaries were within a 20-min driving radius of a chemother-
apy provider than beneficiaries residing in New Jersey or
Connecticut. Similarly, Iowa beneficiaries were less likely
to reside in the same ZIP code as a chemotherapy provider
than beneficiaries residing in Connecticut or New Jersey:
17.9 % when identified by specialty code and proven loca-
tions in Iowa versus 23.5 % in Connecticut and 26.9 % in
New Jersey (Table 3). When identified by chemotherapy
billing codes, 35.0 % of Iowa beneficiaries resided in the
same ZIP code as a provider, a substantial and statistically
significant increase over identification by specialty code
(p < 0.0001). Indeed, this rate was similar to the rate in
Connecticut (36.0 %), although still less than New Jersey
(43.5 %).
Discussion
Access to treatments for cancer, whether geographic or
financial, continues to be of interest to policy makers
and researchers [1, 10, 27, 28]. However, previous papers
estimating geographic access to chemotherapy using
Medicare claims have not assessed whether their results
are sensitive to how chemotherapy providers and service
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locations are identified. We found that the method of
identifying who, but not where, chemotherapy is pro-
vided affected our two measures of geographic access to
chemotherapy.
In our analysis, a number of specialties in addition to
hematology/oncology and medical oncology billed Medi-
care for chemotherapy-related services, with 42.8 % of the
providers associated with chemotherapy claims reporting
a specialty other than hematology/oncology or medical
oncology. Even so, physicians who reported a specialty of
hematology/oncology or medical oncology provided the
vast majority of the chemotherapy services (91.0 % of the
claims).
When we identified chemotherapy providers through
chemotherapy billing codes rather than specialty codes,
we found that average driving-time distances for benefi-
ciaries decreased by almost a quarter and the average
number of providers within 20 min increased two-fold.
An additional 50 % of beneficiaries resided in the same
ZIP code as a chemotherapy provider when providers
were identified using billing codes instead of specialty
codes (35.7 % versus 23.8 %). This suggests that a num-
ber of oncologists might be reporting a specialty other
than hematology/oncology and medical oncology. There
are a number of reasons why this may be the case. First,
all oncologists are trained in internal medicine before
they specialize in oncology. Also, specialty certification
is independent of maintaining one’s license, the former
not mandatory for practice. Finally, accuracy in specialty
code reporting is not required for reimbursement. Any/
all of these factors could cause underreporting of oncol-
ogy specialty codes.
The increase in geographic access to chemotherapy
when providers are identified through chemotherapy
billing codes instead of specialty codes is consistent with
the literature showing underreporting of oncology specialty
on Medicare claims [12, 13]. This does not necessarily
imply that all of the providers associated with chemother-
apy claims were indeed oncologists. It may also be the case
that other specialties truly are providing chemotherapy.
One could concoct a scenario where chemotherapy was
provided by a non-oncologist under extenuating circum-
stances, but to which future provision of chemotherapy
from that same provider is unlikely. Thus there is an
additional dimension which has yet to be explored in
the literature - whether past provision of chemotherapy
is indicative of future access.
Although our measures of geographic access to chemo-
therapy varied substantially by how we identified chemo-
therapy providers, there was no statistical difference across
service location definitions. This was due to the fact that
chemotherapy providers in this sample in general provided
chemotherapy at each location in which they practiced.
There are limitations to our study. First, we only utilize
Medicare claims. Inclusion of additional data would affect
the magnitude of our estimates, as others have found [13].
Unfortunately, NCI no longer releases unencrypted Unique
Physician Identification Number (UPIN) or National Pro-
vider Identifier (NPI), rendering these linkages impossible.
Our contribution to the literature, however, is not providing
Table 2 Estimates of geographic access to chemotherapy by provider and service location definitions






Mean (SD) Median Mean (SD) Median
Number of chemotherapy providers within 20 minutes of beneficiary ZIP Oncology Specialty Codes 21.1 (29.8) 8.0 21.3 (30.0) 8.0
Chemotherapy Billing Codes 41.9 (52.3) 21.0 46.3 (57.3) 23.0
Driving-time distance to nearest chemotherapy provider (minutes) Oncology Specialty Codes 16.1 (20.3) 10.7 15.9 (20.1) 10.6
Chemotherapy Billing Codes 12.2 (16.6) 8.2 11.2 (15.9) 7.3
Data are from SEER-Medicare. Sample included all patients diagnosed with lung cancer that were reported to the SEER registries in 2006. Chemotherapy providers
were identified in one of two ways: by specialty codes reported on Carrier claims (83 for Hematology/Oncology and 90 for Medical Oncology), and by
chemotherapy-related billing codes on Carrier claims (Table 1). Chemotherapy service locations were identified in one of two ways: proven service locations are
locations from where providers billed a chemotherapy-related service, and possible service locations are all locations in which the providers practice. Two geographic
access to care measures are estimated: local area density (the number of chemotherapy providers within 20-minutes driving time of beneficiary ZIP code), and driving-
time distance in minutes between the beneficiary ZIP code centroid and the centroid of the ZIP code of the nearest provider. These measures do not make any
assumptions about whether beneficiaries received chemotherapy or from whom, and are instead a measure of potential access to care
Table 3 Percent of patients residing in the same ZIP code as a









All registries 23.8 % 35.7 % 11.9 % <0.0001
Connecticut 23.5 % 36.0 % 12.4 % <0.0001
Iowa 17.9 % 35.0 % 17.1 % <0.0001
New Jersey 26.9 % 43.5 % 16.6 % <0.0001
Data are from SEER-Medicare. Sample included all patients diagnosed with
lung cancer that were reported to the SEER registries in 2006. Chemotherapy
providers were identified in one of two ways: by specialty codes reported on
Carrier claims (83 for Hematology/Oncology and 90 for Medical Oncology),
and by chemotherapy-related billing codes on Carrier claims (Table 1). Proven
service locations are locations from where providers billed a chemotherapy-
related service, as opposed to possible locations, where providers billed for
any service. These measures do not make any assumptions about whether
beneficiaries received chemotherapy or from whom, and are instead a measure
of potential access to care
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“the” estimate of geographic access to chemotherapy but in-
stead assessing how definitions of “who” and “where” affect
these estimates, something that others have noted might be
an issue but never quantified [12]. In addition, we only
include Carrier claims, which comprise about 75 % of
chemotherapy claims. However the outpatient files do not
include specialty information.
Another limitation is that we only include lung cancer
patients and their providers. However, unless lung cancer
patients are systematically avoiding some chemotherapy
providers by how the providers report their specialty, our
estimates of geographic access to care across definitions of
providers and locations will not be biased. If some oncolo-
gists are sufficiently specialized (e.g. at an NCI-designated
comprehensive cancer center) such that they never treat
lung cancer patients, then they would not be captured in
our analysis. However, these sorts of locations would also
likely have oncologists that do specialize in lung cancer.
Although absolute measures of access would not be accur-
ate, relative measures across the various definitions, our
outcome of interest, would still be valid. We also only
include a single year of data. In doing so we may not cap-
ture physicians and their service locations if they bill
Medicare less than once a year. Finally, our distances are
calculated between ZIP code centroids. We acknowledge
that distances between centroids are not as accurate as
mailing addresses, and that driving times within a centroid
is not zero. In addition, for ZIP codes that cover a large
geographic area, the next closest ZIP code may be more
than 20 min away. If there are no chemotherapy providers
in the same ZIP code as the patient, that area would be
considered as not having access to chemotherapy as we
have defined it. ZIP codes can also change over time,
increasing the complexity of geographic analyses.
Conclusions
Improving geographic access to care and reducing health
disparities have been of interest to healthcare providers
and policy makers for some time and will continue to be
so. Oncology services in particular are estimated to
experience shortages in the coming years due to an
aging population and insufficient growth in the physician
Fig. 2 Access to chemotherapy providers within a 20-min driving-time radius for lung cancer patients. Three representative SEER registries are included:
Iowa, New Jersey and Connecticut. In Panel a, providers were identified using specialty codes. In Panel b, providers were identified by chemotherapy-
related billing codes. Brownish-grey areas indicate that there were no patients diagnosed with lung cancer in that ZIP code during the study period. Green
ZIP codes indicate that a chemotherapy provider was available within 20-min driving time of that ZIP code. No chemotherapy provider was available
within a 20-min driving time for yellow ZIP codes. Maps were created using Microsoft MapPoint 2013
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workforce [29]. The effect is likely heterogeneous, as
demographic compositions vary across areas and over
time due to both aging in place and retirement migra-
tion. To the extent that measures of geographic access
to care affect health policy, it is imperative that these
measures be accurate. Our study suggests that measures
of access to chemotherapy are more sensitive to how
one identifies chemotherapy providers than service loca-
tions. Given that others have shown underreporting in
specialty codes, perhaps both methods of identifying
providers ought to be used to bound estimates of mea-
sures of geographic access to care.
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